2014 Annual Meeting | 2HC.007 - Prevention of Cardioembolic Stroke in Patients with Nonvalvular Atrial Fibrillation: Recommendations Based on Evidence-based Guidelines and Recent Randomized Trials

Date Sunday 04/27/14

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Antonio Culebras, MD, FAHA, FAAN

Topic(s)

Learning Objectives Participants should have clearer ideas on how to identify NVAF in patients with cryptogenic stroke, how to identify patients for treatment with oral anticoagulants, and how to select the best treatment modality to prevent cardioembolic stroke based on new evidence-based practice guidelines.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Tracks Subspecialty in Focus

Recommended Audience Other, Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Didactic, Interactive

Event Timeline
08:00 AM - 08:15 AM		Introduction Antonio Culebras, MD, FAHA, FAAN
08:15 AM - 09:00 AM		Review of New Technologies to Identify AF in Patients with Cryptogenic Stroke Who Would Benefit from Prophylaxis Steven R. Messe, MD, FAHA, FAAN
09:00 AM - 09:45 AM		Selection of Oral Anticoagulants for Prevention of Cardioembolic Stroke in NVAF Gary S. Gronseth, MD, FAAN
09:45 AM - 10:00 AM		Break
10:00 AM - 10:45 AM		Prevention of Cardioembolic Stroke in Specific Populations at Higher Risk of Stroke Including End-Stage Renal Disease, Dementia, Repetitive Falls, and Bleeding Tendencies Carlos S. Kase, MD, FAHA, FAAN
10:45 AM - 11:30 AM		Stroke Risk Prediction and Stratification Schemes in Patients with AF, CHADS2, CHA2DS2-VASc, and HAS-BLED Seemant Chaturvedi, MD, FAHA, FAAN
11:30 AM - 12:00 PM		Conclusions and Recommendations Antonio Culebras, MD, FAHA, FAAN

Faculty Disclosures
Antonio Culebras, MD, FAHA, FAAN	Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for MEDLINK NEUROLOGY. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for MEDLINK NEUROLOGY. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MEDLINK. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MEDLINK. Dr. Culebras has received publishing royalties from a publication relating to health care. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as a RESEARCH REVIEWER with DEPARTMENT OF DEFENSE. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as a REVIEWER with DOD.
Gary S. Gronseth, MD, FAAN	Dr. Gronseth has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain & Life. Dr. Gronseth has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Gronseth has received personal compensation in the range of $0-$499 for serving as a Member/EBM consultant Guideline Development Subcommittee with AAN.
Seemant Chaturvedi, MD, FAHA, FAAN	Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Calgary. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Ramar & Paradiso. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Cole, Scott, Kissane. The institution of Dr. Chaturvedi has received research support from NINDS.
Steven R. Messe, MD, FAHA, FAAN	Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Terumo. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WL Gore. The institution of Dr. Messe has received research support from WL Gore. The institution of Dr. Messe has received research support from Mallinkrodt. The institution of Dr. Messe has received research support from Biogen. Dr. Messe has received intellectual property interests from a discovery or technology relating to health care. Dr. Messe has received publishing royalties from a publication relating to health care. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving as a Clinical Event Committee for the CONFORMAL left atrial appendage occlusion trial with Yale Cardiovascular Research Group.
Carlos S. Kase, MD, FAHA, FAAN	Dr. Kase has nothing to disclose.